AstraZeneca | Cafepharma
Dec 15, 2025 · After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a particular type of breast cancer, the companies have scored …
AstraZeneca | Cafepharma
Dec 22, 2025 · AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns over clotting complications – including deaths – in people taking …
Luye Pharma Buys Rights to Seroquel in China and Other Territories for ...
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international …
Caprelsa | Cafepharma
Aug 23, 2023 · Caprelsa AstraZeneca sells rare cancer drug to Sanofi for up to $300 million Submitted by admin on Mon, 07/27/2015 - 10:00 Read more about AstraZeneca sells rare cancer drug to Sanofi …
AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Aug 1, 2022 · Anonymous board for AstraZeneca.
Airsupra | Cafepharma
Sep 26, 2025 · AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients. AstraZeneca Direct will go …
capivasertib | Cafepharma
Oct 26, 2022 · So Astrazeneca’s news of a win with its contender camizestrant in ER-positive, Her2-negative breast cancer today came as a surprise. Not only that, but Astra today scored a second …
Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab …
Feb 23, 2025 · Anonymous board for Pfizer.
July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in ...
Jul 24, 2025 · AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay …
AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD
AstraZeneca and MedImmune, announced on 5/11/18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive …